Cantor initiated coverage on Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company with five commercialized products. 

The company also collaborates with pharmaceutical companies to bring new molecules to market using its technologies, like PharmFilm. Aquestive is advancing a late-stage proprietary product candidate for severe allergic reactions, including anaphylaxis, and an earlier-stage epinephrine prodrug topical gel for various dermatology conditions.

Cantor highlights that the company’s secret sauce is focused on the PharmFilm technology, which delivers active pharmaceutical ingredients via oral routes (e.g., buccal, sublingual, and lingual). The core focus of the story right now is Anaphylm, which is in pre-NDA stage development for Type 1 allergic reactions.

Cantor initiates with an Overweight rating and a price forecast of $17.

Also Read: Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate

Earlier this month, the company reaffirmed the New Drug Application first quarter 2025 submission guidance for Anaphylm and confirmed that no additional adult clinical trials are necessary before NDA submission. The company has commenced pediatric trials in the U.S. and Canada.

Cantor writes that Aquestive shares are trading well below estimated peak sales for Anaphylm despite the company producing significant data supporting its comparable profile to epinephrine auto-injectors (and, in some situations, improvements).

“We’d be buyers for the potential of this program alone and think shares could be up >200% in 2025 if approved,” the Cantor analyst writes.

Cantor writes that Anaphylm’s sublingual epinephrine could shake up the epinephrine auto-injector market as:

• The product is highly portable, about the size of a postage stamp, and can fit in a pocket or behind a cell phone.
• It may be quicker and easier to use than traditional auto-injectors, with fewer steps involved, which could make it more appealing for patients and caregivers.

Anaphylm U.S. marketing application submission makes up most of Cantor’s revenue projections for Aquestive.

Price Action: AQST stock is up 7.31% at $3.86 at last check Tuesday.

Read Next:

• What’s Going On With AI Drone Company ZenaTech Stock Today?

Image: Shutterstock/ Andrey_Popov.

Latest Ratings for AQST

View More Analyst Ratings for AQST

View the Latest Analyst Ratings

UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.

Get the latest stock analysis from Benzinga?

This article Developer Of EpiPen Alternative Aquestive Stock Undervalued Despite Strong Clinical Data, Analyst Sees Huge Upside originally appeared on Benzinga.com

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.